Publications by authors named "Andrea Boizard-Moracchini"
Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?
Biochim Biophys Acta Rev Cancer
December 2021
Although CD95L (also known as FasL) is still predominantly considered as a death ligand that induces apoptosis in infected and transformed cells, substantial evidence indicate that it can also trigger non-apoptotic signaling pathways whose pathophysiological roles remain to be fully elucidated. The transmembrane ligand CD95L belongs to the tumor necrosis factor (TNF) superfamily. After cleavage by metalloprotease, its soluble form (s-CD95L) fails to trigger the apoptotic program but instead induces signaling pathways promoting the aggressiveness of certain inflammatory disorders such as autoimmune diseases and cancers.
View Article and Find Full Text PDFArticle Synopsis
- Systemic lupus erythematosus (SLE) is an autoimmune disease where the body loses tolerance to its own nucleic acids, leading to autoantibody production and altered T cell functions.
- Plasma from SLE patients shows heightened interactions between platelets and T cells via P-selectin/PSGL-1 engagement, which disrupts T cell regulatory function and enhances inflammatory responses.
- Inhibition of P-selectin in a mouse model of SLE demonstrated potential therapeutic effects, improving key disease symptoms and suggesting this pathway as a target for treatment.
Purpose Of Review: Aberrations in the innate and in the adaptive arms of the immune system play both important roles in the initiation and progression of systemic lupus erythematosus (SLE). The aim of this study was to provide an update on the most recent findings on the cellular pathogenesis of SLE. Our overview focused particularly on results obtained over the last 18 months.
View Article and Find Full Text PDF